

ASX ANNOUNCEMENT

Benitec to present at ASX Spotlight Asia investor conference in Singapore and Hong Kong

Sydney, Australia October 21 2014: Benitec Biopharma Ltd (ASX: BLT) today announced that the Company will present at the ASX Spotlight Asia investor conference in Singapore and Hong Kong this week on the 21st and 23rd of October.

The conferences have been organised by the ASX and the international desks of ASX Broker Participants. The Spotlight Series is an opportunity for select emerging Australian companies to present and to meet with institutional investors, based in South East Asia.

Managing Director and CEO, Dr Peter French will be presenting on behalf of Benitec and a copy of the presentation follows.

For further information regarding Benitec and its activities, please contact the persons below, or visit the Benitec website at www.benitec.com.

Company	Investor relations
Carl Stubbings Chief Business Officer Tel: +61 (2) 9555 6986 Email: cstubbings@benitec.com	Jane Lowe Buchan Consulting Tel: +61 (2) 9237 2807 Email: jlowe@buchanwe.com.au

About Benitec Biopharma Limited:

Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX: BLT, OTC: BTEBY) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as Hepatitis C, Hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington's disease. For more information on Benitec refer to the Company's website at www.benitec.com